프래그먼트 분석 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 기술별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Fragment Analysis Market Summary

The global fragment analysis market size was estimated at USD 254.6 million in 2024 and is projected to reach USD 584.2 million by 2033, growing at a CAGR of 9.75% from 2025 to 2033. The market growth is primarily driven by factors such as increasing adoption of advanced analytical techniques, rising demand for high-precision molecular and protein analysis, expansion of research and development activities in the pharmaceutical and biotechnology sectors, and growing applications in genomics, proteomics, and diagnostics.

Advancements in Technology

Advancements in Technology have emerged as a major demand driver for the fragment analysis market, primarily due to continuous improvements in capillary electrophoresis (CE) platforms and assay chemistry. Higher resolution, quicker run times, enhanced sensitivity, and the ability to analyze multiple fragments simultaneously via sophisticated multiplexing are all features of new-generation CE instruments. These improvements significantly enhance laboratory workflow efficiency, enabling the detection of microsatellites, STRs, SNPs, and other genetic markers with greater accuracy.

Global Fragment Analysis Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global fragment analysis market report based on product & service, technology, application, end use, and region:

• Product & Service Scope Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
• Reagents & Consumables
  • PCR master mixes
  • Fluorescent dyes and labels
  • DNA size standards & ladders
  • Capillary arrays
  • Others
• Services
• Technology Scope Outlook (Revenue, USD Million, 2021 - 2033)
• Capillary Electrophoresis
• Polymerase Chain Reaction
• DNA Sequencing
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Genotyping & Polymorphism Analysis
  • SNP and Indel Genotyping
  • Microsatellite / STR / VNTR Analysis
  • Others
• Molecular Diagnostics
• Forensic & Paternity Testing
• Agricultural & Animal Genomics
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Academic & Research Institutes
• Hospitals & Diagnostic Laboratories
• Biotechnology & Pharmaceutical Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product & Service
    • 1.1.1.2. Technology
    • 1.1.1.3. Application
    • 1.1.1.4. End Use
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objective
  • 1.4.1. Objective 1
  • 1.4.2. Objective2
  • 1.4.3. Objective 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis:
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables and Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing forensic demand for rapid, reliable STR profiling
    • 3.2.1.2. Increasing clinical use for repeat-expansion disorder testing
    • 3.2.1.3. Rising academic need for cost-effective genotyping assays
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Shift toward NGS reduces reliance on capillary electrophoresis
    • 3.2.2.2. Limited throughput restricts suitability for large-scale studies
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis

Chapter 4. Product & Service Business Analysis

• 4.1. Product & Service Segment Dashboard
• 4.2. Fragment Analysis Market: Product & Service Movement Analysis
• 4.3. Instruments
  • 4.3.1. Instruments Market, 2021 - 2033 (USD Million)
• 4.4. Reagents & Consumables
  • 4.4.1. Reagents & Consumables Market, 2021 - 2033 (USD Million)
  • 4.4.2. PCR master mixes
    • 4.4.2.1. PCR master mixes Market, 2021 - 2033 (USD Million)
  • 4.4.3. Fluorescent dyes and labels
    • 4.4.3.1. Fluorescent dyes and labels Market, 2021 - 2033 (USD Million)
  • 4.4.4. DNA size standards & ladders
    • 4.4.4.1. DNA size standards & ladders Market, 2021 - 2033 (USD Million)
  • 4.4.5. Capillary arrays
    • 4.4.5.1. Capillary arrays Market, 2021 - 2033 (USD Million)
  • 4.4.6. Others
    • 4.4.6.1. Others Market, 2021 - 2033 (USD Million)
• 4.5. Services
  • 4.5.1. Services Market, 2021 - 2033 (USD Million)

Chapter 5. Technology Business Analysis

• 5.1. Technology Segment Dashboard
• 5.2. Fragment Analysis Market: Technology Movement Analysis
• 5.3. Capillary Electrophoresis
  • 5.3.1. Capillary Electrophoresis Market, 2021 - 2033 (USD Million)
• 5.4. Polymerase Chain Reaction
  • 5.4.1. Polymerase Chain Reaction Market, 2021 - 2033 (USD Million)
• 5.5. DNA Sequencing
  • 5.5.1. DNA Sequencing Market, 2021 - 2033 (USD Million)
• 5.6. Others
  • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Application Segment Dashboard
• 6.2. Fragment Analysis Market: Application Movement Analysis
• 6.3. Genotyping & Polymorphism Analysis
  • 6.3.1. Genotyping & Polymorphism Analysis Market, 2021 - 2033 (USD Million)
  • 6.3.2. SNP and Indel Genotyping
    • 6.3.2.1. SNP and Indel Genotyping Market, 2021 - 2033 (USD Million)
  • 6.3.3. Microsatellite / STR / VNTR Analysis Market, 2021 - 2033 (USD Million)
    • 6.3.3.1. Microsatellite / STR / VNTR Analysis
  • 6.3.4. Others
    • 6.3.4.1. Others Market, 2021 - 2033 (USD Million)
• 6.4. Molecular Diagnostics
  • 6.4.1. Molecular Diagnostics Market, 2021 - 2033 (USD Million)
• 6.5. Forensic & Paternity Testing
  • 6.5.1. Forensic & Paternity Testing Market, 2021 - 2033 (USD Million)
• 6.6. Agricultural & Animal Genomics
  • 6.6.1. Agricultural & Animal Genomics Market, 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

• 7.1. End Use Segment Dashboard
• 7.2. Fragment Analysis Market: End Use Movement Analysis
• 7.3. Academic & Research Institutes
  • 7.3.1. Academic & Research Institutes Market, 2021 - 2033 (USD Million)
• 7.4. Hospitals & Diagnostic Laboratories
  • 7.4.1. Hospitals & Diagnostic Laboratories Market, 2021 - 2033 (USD Million)
• 7.5. Biotechnology & Pharmaceutical Companies
  • 7.5.1. Biotechnology & Pharmaceutical Companies Market, 2021 - 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Fragment Analysis Market Share By Region, 2024 & 2033
• 8.2. North America
  • 8.2.1. North America Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Regulatory framework
    • 8.2.2.3. Competitive Scenario
    • 8.2.2.4. Target Disease Prevalence
    • 8.2.2.5. U.S. Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Regulatory framework
    • 8.2.3.3. Competitive Scenario
    • 8.2.3.4. Target Disease Prevalence
    • 8.2.3.5. Canada Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Regulatory framework
    • 8.2.4.3. Competitive Scenario
    • 8.2.4.4. Target Disease Prevalence
    • 8.2.4.5. Mexico Fragment Analysis Market, 2021 - 2033 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Regulatory framework
    • 8.3.2.3. Competitive Scenario
    • 8.3.2.4. Target Disease Prevalence
    • 8.3.2.5. UK Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Regulatory framework
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Target Disease Prevalence
    • 8.3.3.5. Germany Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Regulatory framework
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. Target Disease Prevalence
    • 8.3.4.5. France Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Regulatory framework
    • 8.3.5.3. Competitive Scenario
    • 8.3.5.4. Target Disease Prevalence
    • 8.3.5.5. Italy Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Regulatory framework
    • 8.3.6.3. Competitive Scenario
    • 8.3.6.4. Target Disease Prevalence
    • 8.3.6.5. Spain Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Regulatory framework
    • 8.3.7.3. Competitive Scenario
    • 8.3.7.4. Target Disease Prevalence
    • 8.3.7.5. Denmark Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Regulatory framework
    • 8.3.8.3. Competitive Scenario
    • 8.3.8.4. Target Disease Prevalence
    • 8.3.8.5. Sweden Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Regulatory framework
    • 8.3.9.3. Competitive Scenario
    • 8.3.9.4. Target Disease Prevalence
    • 8.3.9.5. Norway Fragment Analysis Market, 2021 - 2033 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Regulatory framework
    • 8.4.2.3. Competitive Scenario
    • 8.4.2.4. Target Disease Prevalence
    • 8.4.2.5. Japan Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Regulatory framework
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Target Disease Prevalence
    • 8.4.3.5. China Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Regulatory framework
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. Target Disease Prevalence
    • 8.4.4.5. India Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.4.5. Australia
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Regulatory framework
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Target Disease Prevalence
    • 8.4.5.5. Australia Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.4.6. Thailand
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Regulatory framework
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Target Disease Prevalence
    • 8.4.6.5. Thailand Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.4.7. South Korea
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Regulatory framework
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. Target Disease Prevalence
    • 8.4.7.5. South Korea Fragment Analysis Market, 2021 - 2033 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive Scenario
    • 8.5.2.4. Target Disease Prevalence
    • 8.5.2.5. Brazil Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.5.3. Argentina
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Target Disease Prevalence
    • 8.5.3.5. Argentina Fragment Analysis Market, 2021 - 2033 (USD Million)
• 8.6. MEA
  • 8.6.1. MEA Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive Scenario
    • 8.6.2.4. Target Disease Prevalence
    • 8.6.2.5. South Africa Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Target Disease Prevalence
    • 8.6.3.5. Saudi Arabia Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Regulatory framework
    • 8.6.4.3. Competitive Scenario
    • 8.6.4.4. Target Disease Prevalence
    • 8.6.4.5. UAE Fragment Analysis Market, 2021 - 2033 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Regulatory framework
    • 8.6.5.3. Competitive Scenario
    • 8.6.5.4. Target Disease Prevalence
    • 8.6.5.5. Kuwait Fragment Analysis Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. Thermo Fisher Scientific
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Danaher
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Agilent Technologies
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. NimaGen
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Genetika Science
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Promega Corporation
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. LGC
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Eurofins Genomics
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. MCLAB
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. SoftGenetics
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives